These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. Tamura K, Aiba K, Saeki T, Nakanishi Y, Kamura T, Baba H, Yoshida K, Yamamoto N, Kitagawa Y, Maehara Y, Shimokawa M, Hirata K, Kitajima M, CINV Study Group of Japan. Int J Clin Oncol; 2015 Oct; 20(5):855-65. PubMed ID: 25681876 [Abstract] [Full Text] [Related]
13. The current status of the use of palonosetron. Navari R. Expert Opin Pharmacother; 2013 Jul; 14(10):1281-4. PubMed ID: 23647207 [Abstract] [Full Text] [Related]
14. Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. Shih V, Wan HS, Chan A. Ann Pharmacother; 2009 Mar; 43(3):444-52. PubMed ID: 19193584 [Abstract] [Full Text] [Related]
17. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics. Hsu ES. Am J Ther; 2010 Mar; 17(5):476-86. PubMed ID: 20844345 [Abstract] [Full Text] [Related]
18. Risk-benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting. Herrstedt J. Expert Opin Drug Saf; 2004 May; 3(3):231-48. PubMed ID: 15155151 [Abstract] [Full Text] [Related]